Don't want to miss the best from Business Standard?
The company had reported a net loss of Rs 2.51 crore for the fourth quarter of last fiscal, SPARC said in a BSE filing.
Total income of the company decreased to Rs 43.13 crore in the quarter ended March 31, 2015 compared with Rs 45.21 crore in the corresponding period last fiscal.
For the year ended March 2015, the company reported a net loss of Rs 39.52 crore as against a net profit of Rs 30.32 crore for the year ended March 2014.
SPARC was demerged from Sun Pharma as a research and drug discovery company in 2007.
Shares of Sun Pharma Advanced Research Company closed 1.47 per cent up at Rs 412 apiece on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%